193 related articles for article (PubMed ID: 36208136)
1. Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited-stage small-cell lung cancer.
Lu M; Zhang R; Qi LS; Wang YL; Sun XX; You J
Thorac Cancer; 2022 Nov; 13(22):3208-3216. PubMed ID: 36208136
[TBL] [Abstract][Full Text] [Related]
2. Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review.
Zhou N; Chen Y; Huang Q; Jiang L; Liao H; Gou H; Lu Y; Che G; Zhang Y
Front Immunol; 2023; 14():1111325. PubMed ID: 36911701
[TBL] [Abstract][Full Text] [Related]
3. Pathological complete response to radical surgery after receiving durvalumab plus neoadjuvant chemotherapy for 1 limited-stage small cell lung cancer patient: a case report.
Li Z; Zhang B; Yang F; Yang L
Transl Cancer Res; 2022 Apr; 11(4):973-979. PubMed ID: 35571672
[TBL] [Abstract][Full Text] [Related]
4. Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer.
Han R; Zhang Y; Wang T; Xiao H; Luo Z; Shen C; Li J; Zhao C; Li L; Zhu M; Du H; Tang H; Ma Z; Wang Y; He Y
Cancer Sci; 2023 Jun; 114(6):2569-2583. PubMed ID: 36880750
[TBL] [Abstract][Full Text] [Related]
5. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.
Rocha P; Zhang J; Laza-Briviesca R; Cruz-Bermúdez A; Bota-Rabassedas N; Sanchez-Espiridon B; Yoshimura K; Behrens C; Lu W; Tang X; Pataer A; Parra ER; Haymaker C; Fujimoto J; Swisher SG; Heymach JV; Gibbons DL; Lee JJ; Sepesi B; Cascone T; Solis LM; Provencio M; Wistuba II; Kadara H
Clin Cancer Res; 2022 Jun; 28(11):2461-2473. PubMed ID: 35394499
[TBL] [Abstract][Full Text] [Related]
6. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
Senan S; Okamoto I; Lee GW; Chen Y; Niho S; Mak G; Yao W; Shire N; Jiang H; Cho BC
Clin Lung Cancer; 2020 Mar; 21(2):e84-e88. PubMed ID: 31948903
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer.
Chen Y; Yan B; Xu F; Hui Z; Zhao G; Liu J; Zhang H; Zeng Z; Zhang R; Provencio M; Ren X; You J
Transl Lung Cancer Res; 2021 May; 10(5):2193-2204. PubMed ID: 34164269
[TBL] [Abstract][Full Text] [Related]
8. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
[TBL] [Abstract][Full Text] [Related]
9. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with
Chemotherapy in Resectable Non-small Cell Lung Cancer].
Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
[TBL] [Abstract][Full Text] [Related]
10. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
[TBL] [Abstract][Full Text] [Related]
11. Pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage IIIB small cell lung cancer: a case report and literature review.
Mei T; Wang T; Lei C; Jiang D; Zhou Q
Front Immunol; 2023; 14():1272450. PubMed ID: 38304254
[TBL] [Abstract][Full Text] [Related]
12. Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.
Heymach JV; Mitsudomi T; Harpole D; Aperghis M; Jones S; Mann H; Fouad TM; Reck M
Clin Lung Cancer; 2022 May; 23(3):e247-e251. PubMed ID: 34819266
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Shirasawa M; Yoshida T; Shiraishi K; Goto N; Yagishita S; Imabayashi T; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yotsukura M; Yoshida Y; Nakagawa K; Naoki K; Tsuchida T; Hamamoto R; Yamamoto N; Motoi N; Kohno T; Watanabe SI; Ohe Y
Br J Cancer; 2023 Dec; 129(12):2003-2013. PubMed ID: 37731022
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab: A Review in Extensive-Stage SCLC.
Al-Salama ZT
Target Oncol; 2021 Nov; 16(6):857-864. PubMed ID: 34731446
[TBL] [Abstract][Full Text] [Related]
15. Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer.
Hu Y; Ren SY; Wang RY; Zeng C; Li JN; Xiao P; Wu F; Yu FL; Liu WL
Front Oncol; 2021; 11():684070. PubMed ID: 34692476
[TBL] [Abstract][Full Text] [Related]
16. [Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC].
Wang H; Han Y
Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):822-832. PubMed ID: 38061884
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
[TBL] [Abstract][Full Text] [Related]
18. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
[TBL] [Abstract][Full Text] [Related]
19. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC.
Yi L; Xu Z; Ma T; Wang C; Wei P; Xiao B; Zhang H; Che N; Liu Z; Han Y
Cancer Immunol Immunother; 2024 Apr; 73(6):99. PubMed ID: 38619623
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer.
Liu W; Zhang T; Zhang Q; Li L; Xu C
BMC Pulm Med; 2022 Dec; 22(1):490. PubMed ID: 36582007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
